<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411411</url>
  </required_header>
  <id_info>
    <org_study_id>1502</org_study_id>
    <nct_id>NCT00411411</nct_id>
  </id_info>
  <brief_title>Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes</brief_title>
  <official_title>Phase 3, Double Blinded, Placebo Controlled Study of the Effects of 12 Weeks DPP-IV Inhibitor Treatment on Secretion and Action of the Incretin Hormones in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We wish to evaluate the effect of long term treatment with a DPP-IV inhibitor on the function
      of the incretin hormones

      Hypothesis We hypothesize that that a gradual improvement in metabolic control induced by
      DPP-IV inhibitor (Januvia®) treatment significantly ameliorates the impaired secretion and
      potency of GLP-1 and leads to a restoration of the lost action of GIP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background The incretin effect, primarily mediated by the peptide hormones GIP and GLP-1, is
      known to be impaired in patients with type 2 diabetes, and characterised by reduced GLP-1
      secretion and potency and a lack of responsiveness to the insulinotropic effect of GIP. The
      cause of this defect remains unknown, but exogenous administration of GLP-1 has shown
      promising results in attempts to restore the incretin effect. Due to rapid degradation of
      both incretin hormones by the enzyme dipeptidyl-peptidase IV (DPP-IV), treatment strategies
      now focus on GLP-1 analogues and prevention of hormone degradation through DPP-IV inhibition.

      Hypothesis We hypothesize that that a gradual improvement in metabolic control induced by
      DPP-IV inhibitor (Januvia®) treatment significantly ameliorates the impaired secretion and
      potency of GLP-1 and leads to a restoration of the lost action of GIP.

      Objective To assess the effect of three months treatment with Januvia®, administered as
      tablets once daily, on metabolic control in metformin treated patients with type 2 diabetes,
      measured as increases in incretin hormones and insulin secretion.

      Efficacy end points Primary efficacy end point in trial part one is the relative increase in
      meal-induced total GLP-1 secretion after one and twelve weeks of Januvia® treatment.

      Primary efficacy end point in part two is restoration of the insulinotropic effect of GIP,
      measured as the relative increase in GIP induced amplification of the late phase insulin
      secretion (AUC) response to glucose after 12 weeks of Januvia® treatment.

      Secondary objectives are examination of GLP-2, somatostatin, glucagon, peptide-YY and two
      glycaemic control parameters (HbA1c and fasting plasma glucose)

      Design This is a single centre, randomized, double blinded, placebo controlled trial. The
      trial consists of two parts, each consisting of three months of inhibitor treatment. In each
      part, 24 patients, recruited from the Diabetes Outpatient Clinic of Gentofte University
      Hospital, will be randomized to a treatment supplement of either Januvia® or placebo.

      Procedures During the trial, patients will be tested with well established procedures. In
      part one, patients will undergo a standardized meal test and two β-cell secretory capacity
      tests. In part two, patients will undergo standardized hyperglycaemic GIP, GLP-1 and saline
      clamps.

      Safety The trial has a short time span of only three months. With more than ten visits during
      this time and regular blood sampling, the patients are well monitored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Relative Increase in Meal-induced Total GLP-1 Secretion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients will be followed for 12 weeks with three meal test examinations; before treatment, after 1 week of treatment and after 12 weeks of treatment. Primary outcome is AUC GLP-1 (pM x 120 as stated).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Restoration of the Insulinotropic Effect of GIP</measure>
    <time_frame>12 weeks</time_frame>
    <description>Restoration of the insulinotropic effect of GIP measured as the relative increase in GIP induced amplification of the late phase insulin secretion (AUC) response to glucose. Patients will be followed for 12 weeks with examinations after 1 and after 12 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examination of GLP-2, Somatostatin, Glucagon, Peptide-YY and Two Glycaemic Control Parameters (HbA1c and Fasting Plasma Glucose)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Secondary objectives are examination of GLP-2, somatostatin, glucagon, peptide-YY and two glycaemic control parameters (HbA1c and fasting plasma glucose). Patients will be followed for 12 weeks with three examinations; before, during and after the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment, administered as tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Januvia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Januvia</intervention_name>
    <description>200 mg t.i.d</description>
    <arm_group_label>Januvia</arm_group_label>
    <other_name>Sitagliptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Type 2 diabetes diagnosed according to and in accordance with the WHO criteria

          -  Metformin treatment of ≥ 1 gram

          -  7,5 % ≤ HbA1c ≤ 10%

          -  Age &gt; 18

          -  BMI ≥ 25 kg/m2

          -  Informed consent

          -  Contraception, if appropriate

        Exclusion criteria

          -  Proliferating retinopathy

          -  Uremia, end stage renal disease, diabetic nephropathy or any other cause of impaired
             renal function with s-creatinine &gt; 130 µM and/or albuminuria (&gt;300 mg/day)

          -  Liver disease with ALAT and/or ASAT &gt; 2 x normal value

          -  Complicated coronary artery disease, NYHA group III and IV

          -  Positive screening for islet cell auto antibodies and/or GAD-65 auto antibodies

          -  Occurrence of type 1 diabetes in first degree relatives

          -  Anaemia

          -  Pregnancy and/or breast feeding

          -  Treatment with medication affecting insulin secretion

          -  non-compliance

        Withdrawal criteria

          -  The subject may withdraw at will at any time

          -  Pregnancy discovered during the trial

          -  Severe illness

          -  Unacceptable side effects

          -  If self-measured fasting plasma glucose on three consecutive days exceeds 15 mM, the
             result is repeated in an immediately scheduled visit, and no treatable intercurrent
             cause for the hyperglycaemia can be found.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kasper Aaboe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <results_first_submitted>May 19, 2014</results_first_submitted>
  <results_first_submitted_qc>July 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2014</results_first_posted>
  <last_update_submitted>July 21, 2014</last_update_submitted>
  <last_update_submitted_qc>July 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Kasper Aaboe</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>GIP</keyword>
  <keyword>Incretin hormones</keyword>
  <keyword>DPP-IV inhibitor</keyword>
  <keyword>Hyperglycaemic clamp</keyword>
  <keyword>Meal test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from Jan. 2008 to Dec 2009 through out-patient clinic and advertisement</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo treatment</description>
        </group>
        <group group_id="P2">
          <title>Januvia</title>
          <description>Active treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo treatment</description>
        </group>
        <group group_id="B2">
          <title>Januvia</title>
          <description>Active treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="31" upper_limit="72"/>
                    <measurement group_id="B2" value="60" lower_limit="39" upper_limit="64"/>
                    <measurement group_id="B3" value="60" lower_limit="31" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Relative Increase in Meal-induced Total GLP-1 Secretion</title>
        <description>Patients will be followed for 12 weeks with three meal test examinations; before treatment, after 1 week of treatment and after 12 weeks of treatment. Primary outcome is AUC GLP-1 (pM x 120 as stated).</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Januvia</title>
            <description>Active treatment
Januvia: 200 mg t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>the Relative Increase in Meal-induced Total GLP-1 Secretion</title>
          <description>Patients will be followed for 12 weeks with three meal test examinations; before treatment, after 1 week of treatment and after 12 weeks of treatment. Primary outcome is AUC GLP-1 (pM x 120 as stated).</description>
          <units>pM x 120 min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2591" spread="358"/>
                    <measurement group_id="O2" value="3959" spread="877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Restoration of the Insulinotropic Effect of GIP</title>
        <description>Restoration of the insulinotropic effect of GIP measured as the relative increase in GIP induced amplification of the late phase insulin secretion (AUC) response to glucose. Patients will be followed for 12 weeks with examinations after 1 and after 12 weeks of treatment.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo treatment, administered as tablets.
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Januvia</title>
            <description>Active treatment
Januvia: 200 mg t.i.d</description>
          </group>
        </group_list>
        <measure>
          <title>Restoration of the Insulinotropic Effect of GIP</title>
          <description>Restoration of the insulinotropic effect of GIP measured as the relative increase in GIP induced amplification of the late phase insulin secretion (AUC) response to glucose. Patients will be followed for 12 weeks with examinations after 1 and after 12 weeks of treatment.</description>
          <units>pM x 120 min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="3.0"/>
                    <measurement group_id="O2" value="21.3" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="3.7"/>
                    <measurement group_id="O2" value="30.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examination of GLP-2, Somatostatin, Glucagon, Peptide-YY and Two Glycaemic Control Parameters (HbA1c and Fasting Plasma Glucose)</title>
        <description>Secondary objectives are examination of GLP-2, somatostatin, glucagon, peptide-YY and two glycaemic control parameters (HbA1c and fasting plasma glucose). Patients will be followed for 12 weeks with three examinations; before, during and after the treatment</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>No adverse events recorded</description>
        </group>
        <group group_id="E2">
          <title>Januvia</title>
          <description>Active treatment. No adverse events recorded</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kasper Aaboe</name_or_title>
      <organization>Gentofte University Hospital</organization>
      <phone>+4522170200</phone>
      <email>kasper@dadlnet.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

